The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery

January 2, 2025 updated by: Rijnstate Hospital

Bariatric guidelines recommend preoperative weight loss of 5% to reduce the risk of surgical complications. However, results in the literature on the improvement of surgical procedure and outcomes are still conflicting.

This study aims to evaluate the effect of preoperative weight loss by means of a 14-day low-calorie diet in bariatric patients on operative time, the ease of the Roux-en-Y gastric bypass (RYGB) procedure and long-term weight loss in a real-life experimental setting.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gelderland
      • Arnhem, Gelderland, Netherlands, 6811AD
        • Rijnstate Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Undergoing primary RYGB surgery (meeting all criteria + approval of surgeon)
  • Able to prepare the meal replacements at home

Exclusion Criteria:

  • Undergoing another bariatric procedure than primary RYGB.
  • Diabetes Mellitus
  • Contraindication for the usage of Modifast meal replacements:

    • Allergy or intolerance to any substance in the used meal replacements (Soy, milk, gluten, egg, peanuts, nuts and seeds)
    • Veganism
    • Kidney failure (GFR < 90 ml/min/1.73m2), liver failure or cardiac insufficiency
    • A heart attack (myocardial infarct) in the past twelve months
    • Cancer
    • Hypokalaemia: serum potassium level <3.4 mmol/l
    • Phenylketonuria & Porphyria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group

Participants in the intervention group will follow a low-calorie diet during 14 days before undergoing surgery. The diet will consist of both meal replacements and regular foods.

For women, the diet provides ± 900 kcal, 50 grams of carbohydrates, 85 grams of protein, 30 grams of fat and 25 grams of fibres.

For men, the diet provides ± 1000 kcal, 55 grams of carbohydrates, 100 grams of protein, 30 grams of fat and 30 grams of fibres.

Participants will be asked to:

  • Use 4 (women) or 5 (men) Modifast meal replacements per day.
  • Daily consume a minimum of 250 grams of (raw) vegetables without dressing.
  • Daily consume 100 grams of lean meat/fish/meat analogues.
  • Daily consume two spoons of liquid oil
  • Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks.
No Intervention: Control group
Participants in the control group can eat according to the standard nutritional advices provided by their dietitian. These advices are intended to educate participants on the recommended eating pattern after surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Operative time of the RYGB procedure
Time Frame: surgery
Duration of the surgical procedure, retrieved from the electronic medical record
surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ease of the RYGB procedure
Time Frame: surgery

Ten aspects of the RYGB procedure will be scored on a 5-point Likert scale. The total score can range from 10 to 50, with 10 being the easiest.

The ten aspects include:

  • Exerting force on instruments (1=very low, 5= very high)
  • Difficulty of moving the liver (1=very easy, 5=very difficult)
  • Size of the liver (1=very small, 5= very large)
  • Size of omentum (1=very small, 5= very large)
  • Difficulty of approaching pouch (1=very easy, 5=very difficult)
  • Accessibility of Treitz ligament (1=very easy, 5=very difficult)
  • Difficulty of creating pouch (1=very easy, 5=very difficult)
  • Difficulty of measuring small intestine (1=very easy, 5=very difficult)
  • Difficulty of entero-entero connection (1=very easy, 5=very difficult)
  • Difficulty of abdominal wall hernia repair (1=very easy, 5=very difficult)
surgery
Appearance of the patient's liver
Time Frame: surgery
Includes four images of the liver in different stages (1= healthy, 2= fatty liver, 3= fatty liver with inflammation, 4= liver cirrhosis). Surgeons will be asked to choose the image that best matches the appearance of the patient's liver.
surgery
Post-operative weight loss
Time Frame: 4 weeks, 3, 6 months and 1, 2, 3, 4, 5 years after surgery
Body weight measurements to assess weight loss after surgery
4 weeks, 3, 6 months and 1, 2, 3, 4, 5 years after surgery

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of the diet
Time Frame: During the 14-day intervention period
Feasibility will be assessed via questionnaires
During the 14-day intervention period
Compliance of the diet
Time Frame: During the 14-day intervention period
Compliance will be assessed via food records
During the 14-day intervention period
Complication rate
Time Frame: First 30 days post-surgery
All short term complications during the first 30 days will be recorded and classified according to the Clavien-Dindo classification
First 30 days post-surgery
Wound healing
Time Frame: 4 weeks
Degree of wound healing post-surgery will be checked based on appearance on a 5-point Likert scale.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Eric J Hazebroek, MD, PhD, Vitalys, part of Rijnstate hospital/Wageningen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 29, 2020

Primary Completion (Actual)

June 22, 2022

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

June 12, 2020

First Submitted That Met QC Criteria

June 15, 2020

First Posted (Actual)

June 16, 2020

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 2, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Morbid Obesity

Clinical Trials on 14-day Low Calorie Diet

Subscribe